MedTrace Logo

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

NCT06622486 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-11-07

No results posted yet for this study

Summary

This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

EGL-001

IV administration

Sponsors & Collaborators

  • Egle Therapeutics

    lead INDUSTRY

Principal Investigators

  • Pejvack Motlagh, MD · Egle Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-27
Primary Completion
2027-01-23
Completion
2027-01-23

Countries

  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06622486 on ClinicalTrials.gov